AAV1.NT-3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia.

Lingying TongBurcak OzesKyle MossMorgan MyersAlicia RidgleyZarife Sahenk

Published in: Journal of cachexia, sarcopenia and muscle (2023)

This study shows that AAV1.NT-3 gene therapy protected SOD1KO mouse from accelerated aging effects functionally and histologically. We further confirmed that NT-3 has potential to activate the mTOR and glycolytic pathways in muscle.

Keyphrases

gene therapy
mouse model
skeletal muscle
amyotrophic lateral sclerosis
cell proliferation
human health
risk assessment
climate change
community dwelling